Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
Фаза 2
Завершено
NCT01939353
| Заболевание | Adult ADHD |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| Статус | Завершено |
|---|
| Участники | 45 участн. |
|---|
| Вмешательство | CTN SR |
|---|
| Дата начала | 3.10.2013 |
|---|
| Дата завершения | 20.02.2014 |
|---|
| Публикация результатов | 18.10.2021 |
|---|
Кратко
This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release \[CTN SR\]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Attention-Deficit Hyperactivity Disorder (ADHD) on the Mini International Neuropsychiatric Interview Plus, Version 6.0 (M.I.N.I.-Plus). Evaluations included determining an effectiveness signal for ADHD and related symptoms and exploring dosing, tolerability, onset of action, and duration of effect. Dose-response/tolerability relationships with CTN SR were also explored. The 1-week placebo run-in \[single-blind (SB)\] was also used for informal safety comparison purposes.
Change From Baseline-2 in ADHD Symptoms to Week 4 as Assessed by the Adult Attention-Deficit Hyperactivity Disorder Rating Scale (AD HD-RS-IV)
Baseline, Week 4 · score on a scale
| Centanafadine SR 100-500 mg | 38.70 ± 6.19 score on a scale |
|---|
| Centanafadine SR 100-500 mg | -21.41 ± 10.74 score on a scale |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.